Information between 9th July 2025 - 19th July 2025
Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.
| Division Votes |
|---|
|
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context Michael Wheeler voted Aye - in line with the party majority and in line with the House One of 333 Labour Aye votes vs 47 Labour No votes Tally: Ayes - 336 Noes - 242 |
|
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context Michael Wheeler voted No - in line with the party majority and in line with the House One of 377 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 103 Noes - 416 |
|
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context Michael Wheeler voted No - in line with the party majority and in line with the House One of 356 Labour No votes vs 8 Labour Aye votes Tally: Ayes - 35 Noes - 469 |
|
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context Michael Wheeler voted No - in line with the party majority and in line with the House One of 331 Labour No votes vs 47 Labour Aye votes Tally: Ayes - 149 Noes - 334 |
|
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context Michael Wheeler voted No - in line with the party majority and in line with the House One of 377 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 175 Noes - 401 |
|
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context Michael Wheeler voted Aye - in line with the party majority and in line with the House One of 330 Labour Aye votes vs 37 Labour No votes Tally: Ayes - 335 Noes - 135 |
|
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context Michael Wheeler voted No - in line with the party majority and in line with the House One of 364 Labour No votes vs 7 Labour Aye votes Tally: Ayes - 105 Noes - 370 |
|
9 Jul 2025 - Universal Credit and Personal Independence Payment Bill - View Vote Context Michael Wheeler voted No - in line with the party majority and in line with the House One of 333 Labour No votes vs 35 Labour Aye votes Tally: Ayes - 130 Noes - 443 |
|
15 Jul 2025 - Welfare Spending - View Vote Context Michael Wheeler voted No - in line with the party majority and in line with the House One of 344 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 106 Noes - 440 |
|
15 Jul 2025 - Taxes - View Vote Context Michael Wheeler voted No - in line with the party majority and in line with the House One of 333 Labour No votes vs 0 Labour Aye votes Tally: Ayes - 165 Noes - 342 |
|
16 Jul 2025 - Competition - View Vote Context Michael Wheeler voted Aye - in line with the party majority and in line with the House One of 313 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 333 Noes - 54 |
|
16 Jul 2025 - Competition - View Vote Context Michael Wheeler voted Aye - in line with the party majority and in line with the House One of 314 Labour Aye votes vs 0 Labour No votes Tally: Ayes - 334 Noes - 54 |
| Speeches |
|---|
|
Michael Wheeler speeches from: Business of the House
Michael Wheeler contributed 1 speech (119 words) Thursday 17th July 2025 - Commons Chamber Leader of the House |
| Written Answers |
|---|
|
Pancreatic Enzyme Replacement Therapy: Supply Chains
Asked by: Michael Wheeler (Labour - Worsley and Eccles) Thursday 17th July 2025 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that lessons learned from the COVID-19 Vaccine Taskforce will inform its approach to managing the shortages of pancreatic enzyme replacement therapy (PERT). Answered by Karin Smyth - Minister of State (Department of Health and Social Care) The Department has not conducted a 360-degree supply and demand forecast for pancreatic enzyme replacement therapy (PERT). However, the Department is in regular discussion with suppliers of PERT on the latest stock availability and the actions that are being taken to mitigate the supply issue, including what steps suppliers are taking to ensure future supplies meet the long-term needs for patients in the United Kingdom. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market. In the longer term, the Department has had interest from non-UK suppliers of PERT wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency, we are working with these potential suppliers, and if authorised, these products could further diversify and strengthen the market. While the Department's approach for managing the supply issues with PERT is not specifically informed by the COVID-19 Vaccines Taskforce experience, as we are continually learning and seeking to improve the way we work to both manage and help prevent supply issues for PERT. |
|
Pancreatic Enzyme Replacement Therapy: Supply Chains
Asked by: Michael Wheeler (Labour - Worsley and Eccles) Thursday 17th July 2025 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, whether his Department has conducted a 360-degree supply and demand forecast for pancreatic enzyme replacement therapy to assess the long-term needs for patients. Answered by Karin Smyth - Minister of State (Department of Health and Social Care) The Department has not conducted a 360-degree supply and demand forecast for pancreatic enzyme replacement therapy (PERT). However, the Department is in regular discussion with suppliers of PERT on the latest stock availability and the actions that are being taken to mitigate the supply issue, including what steps suppliers are taking to ensure future supplies meet the long-term needs for patients in the United Kingdom. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market. In the longer term, the Department has had interest from non-UK suppliers of PERT wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency, we are working with these potential suppliers, and if authorised, these products could further diversify and strengthen the market. While the Department's approach for managing the supply issues with PERT is not specifically informed by the COVID-19 Vaccines Taskforce experience, as we are continually learning and seeking to improve the way we work to both manage and help prevent supply issues for PERT. |
| Select Committee Documents |
|---|
|
Tuesday 15th July 2025
Oral Evidence - 2025-07-15 11:30:00+01:00 Outside employment and interests - Committee on Standards Found: ; Dr Rose Marie Parr; Anna Sabine; Dr Neil Shastri-Hurst; Victoria Smith; Dr David Stirling; Michael Wheeler |
|
Thursday 10th July 2025
Special Report - 2nd Special Report - Register of Interests of Members’ Staff: Government Response Committee on Standards Found: Smith (Lay member) Gareth Snell (Labour; Stoke-on-Trent Central) Dr David Stirling (Lay member) Michael Wheeler |
| Bill Documents |
|---|
|
Jul. 09 2025
Bill 259 2024-25 (as introduced) Letter Boxes (Positioning) Bill 2024-26 Bill Found: Foody, Louise Haigh, Sally Jameson, Joe Morris, Sarah Owen, Laurence Turner, Chris Webb and Michael Wheeler |
| APPG Publications |
|---|
|
Maternity APPG Document: Minutes Maternity APPG Inaugural Meeting 10 March 2025.docx Found: MP (Rochdale), Michelle Welsh MP (Sherwood Forest), Andrew Western MP (Stretford and Urmston), Michael Wheeler |
| Calendar |
|---|
|
Wednesday 16th July 2025 10 a.m. Committee of Privileges - Private Meeting View calendar - Add to calendar |
|
Tuesday 9th September 2025 10 a.m. Committee on Standards - Private Meeting View calendar - Add to calendar |